<p>Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR^TM In Patients With AML And Their Clinical Impact In Mexico City</p>

• DOI: 10.2147/ott.s219703
• Publication Date: 2019-09-30T23:41:35Z
• Authors: Irma Olarte-Carrillo; Anel Garcia Laguna; Christian Omar Ra...; Brenda Arratia Gu...; Federico Centeno ...; Jhoana Paredes Sa...; Etta Rozen Fuller; Juan Julio Kassac...; Juan Collazo Jaloma; Adolfo Martinez T...
• Keywords: Isocitrate dehydrogenase; IDH2

Approximately 40-50% of patients with acute myeloid leukaemia (AML) have been reported to present a normal karyotype and variable disease-free period, most likely due the molecular heterogeneity presented by these patients. A variety mutations identified at level, such as those in IDH1/2 gene, which causes gain function isocitrate dehydrogenase enzyme, generating high levels (R)-2-hydroxyglutarate oncometabolite, competitively inhibits dioxygenase enzymes. Therefore, objective this study was evaluate incidence gene AML their impact on survival.A total 101 diagnosis were included; mononuclear cells obtained for DNA extraction purification. Mutations detected using TaqMan™ competitive allele-specific probes (castPCR™). Overall survival curves plotted IBM SPSS Statistics 23 software.The frequency IDH 19.8%. For IDH1 13.8% included R132H, V178I, G105G R132C. The IDH2 5.9%; variants R172K R140Q. mean time without 173.15 days (120.20-226.10), while 54.95 (9.7-100.18), p = 0.001.The sample similar that other studies. analysis is great importance prognostic factor use potential therapeutic targets or inhibitors IDH1(Ivosidenib, Tibsovo) (Enasidenib, Idhifa).